This is an old revision of this page, as edited by CheMoBot (talk | contribs) at 20:41, 23 October 2011 (Updating {{drugbox}} (changes to verified fields - updated 'ChemSpiderID_Ref', 'UNII_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'CAS_number_Ref') per Chem/Drugbox validation (report [[Misplaced Pages...). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 20:41, 23 October 2011 by CheMoBot (talk | contribs) (Updating {{drugbox}} (changes to verified fields - updated 'ChemSpiderID_Ref', 'UNII_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'CAS_number_Ref') per Chem/Drugbox validation (report [[Misplaced Pages...)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compound| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | TWEAK receptor |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C6334H9792N1700O2000S42 |
| Molar mass | 143.1 kDa g·mol |
| (what is this?) (verify) | |
Enavatuzumab is a humanized monoclonal antibody used in the treatment of solid tumors.
Enavatuzumab was developed by Facet Biotech Corp.
References
- "Statement On A Nonproprietary Name Adopted By The USAN Council: Enavatuzumab" (PDF). American Medical Association.
 | This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it. |